β-galactosidase-targeted senolytic prodrug ameliorates preclinical models of post-traumatic osteoarthritis
Funded by the Regional Innovation Joint Fund of the National Natural Science Foundation of China (Integrated Project) (U23A6009), the National Natural Science Foundation of China (82202687, 82172420, and 82072486), the Beijing Municipal Natural Science Foundation (7222213), and the Capital's Funds for Health Improvement and Research (2022-4-20511), and Beijing Tongren Hospital Seed Funds (2021-YJJ-ZZL-008).
Authors
- Jin Cheng (ORCID: https://orcid.org/0000-0001-5724-2375)
- Tong Wu (ORCID: https://orcid.org/0000-0002-6856-5070)
- Yingfang Ao (ORCID: https://orcid.org/0000-0002-8909-2022)
- M J Sun (ORCID: https://orcid.org/0009-0006-9155-726X)
- Xiaoqing Hu (ORCID: https://orcid.org/0000-0001-9824-1109)
- Hongkui Deng (ORCID: https://orcid.org/0000-0003-3045-4428)
- Qi Li (ORCID: https://orcid.org/0000-0001-6255-877X)
- Junyan Wang (ORCID: https://orcid.org/0009-0007-1047-3783)
- Xi Gong
- Boyang Xu
- Yifei Fan (ORCID: https://orcid.org/0000-0001-7367-7045)
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- EBioMedicine
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1016/j.ebiom.2025.106015
- Citations
- 1
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.67